Jianfeng Zhou - Dissemin

All papers authored by Jianfeng Zhou

This paper was not found in any repository; the policy of its publisher is unknown or unclear.

2024 Gang An, Daobin Zhou, Shu Cheng, Keshu Zhou, Jianyong Li, Jianfeng Zhou

, Liping Xie, Jie Jin, Liye Zhong, Lingzhi Yan, Haiyi Guo, Chenmu Du, Jinhua Zhong, Yiling Yu, Binghao Wu and 1 other authors

Supplementary Data from A Phase II Trial of the Bruton Tyrosine-Kinase Inhibitor Zanubrutinib (BGB-3111) in Patients with Relapsed/Refractory Waldenström Macroglobulinemia

Upload

Gang An, Daobin Zhou, Shu Cheng, Keshu Zhou, Jianyong Li, Jianfeng Zhou

, Liping Xie, Jie Jin, Liye Zhong, Lingzhi Yan, Haiyi Guo, Chenmu Du, Jinhua Zhong, Yiling Yu, Binghao Wu and 1 other authors

Figure S1 from A Phase II Trial of the Bruton Tyrosine-Kinase Inhibitor Zanubrutinib (BGB-3111) in Patients with Relapsed/Refractory Waldenström Macroglobulinemia

Upload

Gang An, Daobin Zhou, Shu Cheng, Keshu Zhou, Jianyong Li, Jianfeng Zhou

, Liping Xie, Jie Jin, Liye Zhong, Lingzhi Yan, Haiyi Guo, Chenmu Du, Jinhua Zhong, Yiling Yu, Binghao Wu and 1 other authors

Table S3 from A Phase II Trial of the Bruton Tyrosine-Kinase Inhibitor Zanubrutinib (BGB-3111) in Patients with Relapsed/Refractory Waldenström Macroglobulinemia

Upload

Gang An, Daobin Zhou, Shu Cheng, Keshu Zhou, Jianyong Li, Jianfeng Zhou

, Liping Xie, Jie Jin, Liye Zhong, Lingzhi Yan, Haiyi Guo, Chenmu Du, Jinhua Zhong, Yiling Yu, Binghao Wu and 1 other authors

Table S1 from A Phase II Trial of the Bruton Tyrosine-Kinase Inhibitor Zanubrutinib (BGB-3111) in Patients with Relapsed/Refractory Waldenström Macroglobulinemia

Upload

Gang An, Daobin Zhou, Shu Cheng, Keshu Zhou, Jianyong Li, Jianfeng Zhou

, Liping Xie, Jie Jin, Liye Zhong, Lingzhi Yan, Haiyi Guo, Chenmu Du, Jinhua Zhong, Yiling Yu, Binghao Wu and 1 other authors

Figure S2 from A Phase II Trial of the Bruton Tyrosine-Kinase Inhibitor Zanubrutinib (BGB-3111) in Patients with Relapsed/Refractory Waldenström Macroglobulinemia

Upload

Gang An, Daobin Zhou, Shu Cheng, Keshu Zhou, Jianyong Li, Jianfeng Zhou

, Liping Xie, Jie Jin, Liye Zhong, Lingzhi Yan, Haiyi Guo, Chenmu Du, Jinhua Zhong, Yiling Yu, Binghao Wu and 1 other authors

Data from A Phase II Trial of the Bruton Tyrosine-Kinase Inhibitor Zanubrutinib (BGB-3111) in Patients with Relapsed/Refractory Waldenström Macroglobulinemia

Upload

Gang An, Daobin Zhou, Shu Cheng, Keshu Zhou, Jianyong Li, Jianfeng Zhou

, Liping Xie, Jie Jin, Liye Zhong, Lingzhi Yan, Haiyi Guo, Chenmu Du, Jinhua Zhong, Yiling Yu, Binghao Wu and 1 other authors

Figure S3 from A Phase II Trial of the Bruton Tyrosine-Kinase Inhibitor Zanubrutinib (BGB-3111) in Patients with Relapsed/Refractory Waldenström Macroglobulinemia

Upload

Gang An, Daobin Zhou, Shu Cheng, Keshu Zhou, Jianyong Li, Jianfeng Zhou

, Liping Xie, Jie Jin, Liye Zhong, Lingzhi Yan, Haiyi Guo, Chenmu Du, Jinhua Zhong, Yiling Yu, Binghao Wu and 1 other authors

Table S2 from A Phase II Trial of the Bruton Tyrosine-Kinase Inhibitor Zanubrutinib (BGB-3111) in Patients with Relapsed/Refractory Waldenström Macroglobulinemia

Upload

Xiaojian Zhu, Zhengtao Zhou, Haitao Ruan, Ting Deng, Fankai Meng, Yang Cao, Liang Huang, Xiaoxi Zhou, Jianfeng Zhou

A Real-world cost-effectiveness study of autologous stem cell transplant plus CAR-T versus CAR-Ttherapy alone in Chinese patients with relapsed/refractory large B-cell lymphoma

Upload

2023 Yuqin Song, Quanli Gao, Huilai Zhang, Lei Fan, Jianfeng Zhou

, Dehui Zou, Wei Li, Haiyan Yang, Ting Liu, Quanshun Wang, Fangfang Lv, Haiyi Guo, Xia Zhao, Dan Wang, Pei Zhang and 7 other authors

Supplementary Data from Tislelizumab for Relapsed/Refractory Classical Hodgkin Lymphoma: 3-Year Follow-up and Correlative Biomarker Analysis

Upload

Yuqin Song, Quanli Gao, Huilai Zhang, Lei Fan, Jianfeng Zhou

, Dehui Zou, Wei Li, Haiyan Yang, Ting Liu, Quanshun Wang, Fangfang Lv, Haiyi Guo, Xia Zhao, Dan Wang, Pei Zhang and 7 other authors

Data from Tislelizumab for Relapsed/Refractory Classical Hodgkin Lymphoma: 3-Year Follow-up and Correlative Biomarker Analysis

Upload

This paper is made freely available by the publisher.

Wei Xu, Keshu Zhou

, Tingyu Wang, Shenmiao Yang, Lihong Liu, Yu Hu

, Wei Zhang, Kaiyang Ding, Jianfeng Zhou

, Sujun Gao, Bing Xu

, Zunmin Zhu, Ting Liu

, Huilai Zhang, Jianda Hu

and 10 other authors

Orelabrutinib in relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma patients: Multi‐center, single‐arm, open‐label, phase 2 study

Download from onlinelibrary.wiley.com

2022 Guan-Nan Li, Xue-Jiao Zhao, Zhen Wang, Meng-Shi Luo, Shen-Nan Shi, Dan-Mei Yan, Hua-Yi Li, Jia-Hao Liu, Yang Yang, Jia-Hong Tan, Ze-Yu Zhang, Ru-Qi Chen, Hui-Ling Lai, Xiao-Yuan Huang

, Jian-Feng Zhou

and 3 other authors

Elaiophylin triggers paraptosis and preferentially kills ovarian cancer drug-resistant cells by inducing MAPK hyperactivation

Download from doi.org

This paper was not found in any repository, but could be made available legally by the author.

Yuting Tang

, Qian Xu, Hui Luo, Xiaomei Yan, Gaoxiang Wang, Liang Hu, Jin Jin, David P. Witte, Rebecca A. Marsh, Liang Huang, Gang Huang, Jianfeng Zhou

Excessive IL-10 and IL-18 trigger hemophagocytic lymphohistiocytosis–like hyperinflammation and enhanced myelopoiesis

Upload

Yuqin Song, Mingyuan Sun, Junyuan Qi, Wei Xu, Jianfeng Zhou

, Dengju Li, Jianyong Li, Lugui Qiu, Chenmu Du, Haiyi Guo, Jane Huang, Zhiyu Tang, Ying Ou, Binghao Wu, Yiling Yu and 1 other authors

A two‐part, single‐arm, multicentre, phase I study of zanubrutinib, a selective Bruton tyrosine kinase inhibitor, in Chinese patients with relapsed/refractory B‐cell malignancies

Download from onlinelibrary.wiley.com

Yuqin Song, Quanli Gao, Huilai Zhang, Lei Fan, Jianfeng Zhou

, Dehui Zou, Wei Li, Haiyan Yang, Ting Liu, Quanshun Wang, Fangfang Lv, Haiyi Guo, Xia Zhao

, Dan Wang, Pei Zhang and 7 other authors

Tislelizumab for Relapsed/Refractory Classical Hodgkin Lymphoma: 3-Year Follow-up and Correlative Biomarker Analysis

Download from aacrjournals.org

Jiaqi Tan

, Lei Zhao

, Gaoxiang Wang

, Tongjuan Li

, Dan Li

, Qian Xu

, Xing Chen

, Zhen Shang

, Jue Wang

, Jianfeng Zhou

Corrigendum to “Human MLL-AF9 Overexpression Induces Aberrant Hematopoietic Expansion in Zebrafish”

Download from downloads.hindawi.com

2021 Jiaying Wu

, Fankai Meng, Yang Cao, Yicheng Zhang, Xiaojian Zhu

, Na Wang, Jue Wang, Lifang Huang, Jianfeng Zhou

, Yi Xiao

Sequential CD19/22 CAR T-cell immunotherapy following autologous stem cell transplantation for central nervous system lymphoma

Download from www.nature.com

Gang An, Daobin Zhou, Shu Cheng, Keshu Zhou, Jianyong Li, Jianfeng Zhou

, Liping Xie, Jie Jin

, Liye Zhong, Lingzhi Yan, Haiyi Guo, Chenmu Du, Jinhua Zhong, Yiling Yu

, Binghao Wu and 1 other authors

A Phase II Trial of the Bruton Tyrosine-Kinase Inhibitor Zanubrutinib (BGB-3111) in Patients with Relapsed/Refractory Waldenström Macroglobulinemia

Download from aacrjournals.org

Yuting Tang, Qian Xu, Liang Hu, Xiaomei Yan, Xiaomin Feng, Asumi Yokota, Weinan Wang

, Di Zhan, Durga Krishnamurthy, David E. Ochayon, Lijun Wen, Li Huo, Huimin Zeng, Yingwan Luo, L. Frank Huang and 6 other authors

Tumor Microenvironment–Derived R-spondins Enhance Antitumor Immunity to Suppress Tumor Growth and Sensitize for Immune Checkpoint Blockade Therapy

Upload

Missing publications? Search for publications with a matching author name.

Researcher

Statistics

Refine

All papers authored by Jianfeng Zhou